Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: The first European Group on Graves' Orbitopathy experience

European Journal of Endocrinology

Volumn 148, Issue 5, 2003, Pages 491-495

  Prummel, Mark F ⁱ   Bakker, Annemieke ⁱ   Wiersinga, Wilmar M ⁱ   Baldeschi, Lelio ⁱ   Mourits, Maarten P ^a   Kendall Taylor, Pat ^b   Perros, Petros ^b   Neoh, Chris ^b   Dickinson, A Jane ^b   Lazarus, John H ^c   Lane, Carol M ^c   Heufelder, Armin E ^d   Kahaly, George J ^e   Pitz, Suzanne ^e   Orgiazii, Jacques ^f   Hullo, Alain ^f   Pinchera, Aldo ^g   Marcocci, Claudio ^g   Sartini, Maria S ^g   Rocchi, Roberto ^g   Nardi, Marco ^g   Krassas, Gerry E ^h   Halkias, A ^h   more..

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f CENTRE HOSPITALIER   (France)

^g UNIVERSITY OF PISA   (Italy)

^h PANAGIA GENERAL HOSPITAL   (Greece)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; ANTITHYROID AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; OCTREOTIDE; RADIOACTIVE IODINE;

ADULT; ARTICLE; CATARACT; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE SEVERITY; EUROPE; EXOPHTHALMOS; EYE DISEASE; EYE MOVEMENT DISORDER; FAMILY HISTORY; FEASIBILITY STUDY; FEMALE; GLAUCOMA; GRAVES DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KERATOPATHY; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MEDICAL RECORD; MULTICENTER STUDY; OPTIC NERVE DISEASE; ORBIT DISEASE; PATIENT REFERRAL; PRIORITY JOURNAL; SKIN DISEASE; SOFT TISSUE DISEASE; THYROID DISEASE; TREATMENT PLANNING; VISUAL SYSTEM EXAMINATION;

ADULT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GRAVES DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 0037763786     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1480491     Document Type: Article

References (15)

1. Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF & Wiersinga WM. Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study instrument. Thyroid 1997 7 885-889.
2. Burch HB & Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocrine Reviews 1993 14 747-793.
3. Bartalena L, Pinchera A & Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocrine Reviews 2000 21 168-199.
4. Wiersinga WM & Prummel MF. An evidence-based approach to the treatment of Graves' ophthalmopathy. Endocrinology and Metabolism Clinics of North America 2000 29 297-319.
5. Garrity JA, Terwee CB, Feldon SE & Wiersinga WM. Assessment of disease severity. In Recent Developments in Graves' Ophthalmopathy, pp 39-57. Ed. MF Prummel. Boston: Kluwer Academic Publishers, 2000.
6. Dickinson JA & Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clinical Endocrinology 2001 55 283-303.
7. Werner SC. Modification of the classification of eye changes of Graves' disease: recommendations of the committee of the American Thyroid Association. Journal of Clinical Endocrinology and Metabolism 1977 44 203-204.
8. Bahn RS & Gorman CA. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinology and Metabolism Clinics of North America 1987 16 391-407.
9. Prummel MF, Mourits MP, Berghout A, Krenning EP, Van der Gaag R, Koornneef L et al. Prednisone and cylcosporine in the treatment of severe Graves' ophthalmopathy. New England Journal of Medicine 1989 321 1353-1359.
10. Mourits MP, Prummel MF, Wiersinga WM & Koorneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clinical Endocrinology 1997 47 9-14.
11. Prummel MF, Wiersinga WM & Mourits MP. Assessment of disease activity of Graves' ophthalmopathy. In Recent Developments in Graves' Ophthalmopathy, pp 59-80. Ed. MF Prummel. Boston: Kluwer Academic Publishers, 2000.
12. Krassas GE & Kahaly GJ. The role of octreoscan in thyroid eye disease. European Journal of Endocrinology 1999 140 373-375.
13. Gorman CA. Temporal relationship between onset of Graves' ophthalmopathy and diagnosis of thyrotoxicosis. Mayo Clinic Proceedings 1983 58 515-519.
14. Wiersinga WM, Smit T, Van der Gaag R & Koornneef L. Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease. Journal of Endocrinology Investigations 1988 11 615-619.
15. Weetman AP & Wiersinga WM. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey. Clinical Endocrinology 1998 49 21-28.